Search hospitals > Washington > Bellevue

Swedish Cancer Institute-Eastside Oncology Hematology

Claim this profile
Bellevue, Washington 98005
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Breast cancer
Conducts research for Ovarian Cancer
Conducts research for Cervical Cancer
41 reported clinical trials
0 medical researchers
Photo of Swedish Cancer Institute-Eastside Oncology Hematology in BellevuePhoto of Swedish Cancer Institute-Eastside Oncology Hematology in BellevuePhoto of Swedish Cancer Institute-Eastside Oncology Hematology in Bellevue

Summary

Swedish Cancer Institute-Eastside Oncology Hematology is a medical facility located in Bellevue, Washington. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Ovarian Cancer, Cervical Cancer and other specialties. Swedish Cancer Institute-Eastside Oncology Hematology is involved with conducting 41 clinical trials across 100 conditions. There are 0 research doctors associated with this hospital, such as .

Area of expertise

1Lung Cancer
Global Leader
Swedish Cancer Institute-Eastside Oncology Hematology has run 11 trials for Lung Cancer. Some of their research focus areas include:
Stage I
Stage II
Stage III
2Breast Cancer
Swedish Cancer Institute-Eastside Oncology Hematology has run 7 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
ER positive
Stage IV

Top PIs

Clinical Trials running at Swedish Cancer Institute-Eastside Oncology Hematology

Lung Cancer
ALK Gene Rearrangement
Anaplastic Large Cell Lymphoma
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria

Similar Hospitals nearby

Select from list below to view details

Frequently asked questions

What kind of research happens at Swedish Cancer Institute-Eastside Oncology Hematology?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security